Mural Oncology Approves Acquisition by XRA 5 Corp.

Mural Oncology Plc ( (MURA) ) has issued an announcement.

On October 24, 2025, Mural Oncology plc held a special meeting and an extraordinary general meeting to discuss the acquisition of its entire share capital by XRA 5 Corp., a subsidiary of XOMA Royalty Corporation. The acquisition, to be executed through a scheme of arrangement under Irish law, received overwhelming shareholder approval, with the majority voting in favor of the proposals necessary to proceed. The acquisition is anticipated to finalize in the fourth quarter of 2025, pending customary closing conditions and court sanctioning, potentially impacting the company’s market position and stakeholder interests.

The most recent analyst rating on (MURA) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Mural Oncology Plc stock, see the MURA Stock Forecast page.

Spark’s Take on MURA Stock

According to Spark, TipRanks’ AI Analyst, MURA is a Neutral.

Mural Oncology Plc’s stock is weighed down by its financial challenges, including zero revenue and high cash burn, which significantly impact its overall score. Technical indicators suggest some positive momentum, but the stock faces resistance. Valuation remains unattractive due to unprofitability. However, upcoming clinical milestones and strategic focus on efficiency provide potential upside, reflected in the corporate events score.

To see Spark’s full report on MURA stock, click here.

More about Mural Oncology Plc

Mural Oncology plc is a company operating in the oncology sector, focusing on cancer treatment and research. The company is involved in the development and provision of oncology-related products and services, with a market focus on innovative cancer therapies.

Average Trading Volume: 288,955

Technical Sentiment Signal: Sell

Current Market Cap: $36.38M

For an in-depth examination of MURA stock, go to TipRanks’ Overview page.